Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Pri
Jan 13, 2023•26 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Neoadjuvant (pre-surgical) immune checkpoint blockade may prevent cancer relapse and progression.This treatment approach is now FDA-approved for resectable triple-negative breast cancer, and hundreds of clinical trials in other cancers are ongoing.Surgical resection specimens collected after several weeks of neoadjuvant ICB offer vast opportunities for predictive biomarker discovery and understanding ICB response/resistance. Suzanne Topalian, MD, Associate Director / Professor of Surgery, Bloomberg~Kimmel Institute for Cancer Immunotherapy / Johns Hopkins University Learn more about the IO360° Summit at www.io360summit.com
For the best experience, listen in Metacast app for iOS or Android